Amgen Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Amgen Stock Forecast and Price Target
Amgen's most recent price target of $317.25 for 2024 was provided by eight renowned analysts over the past few months, with an average prediction of $317.25. If this prediction is correct, Amgen's stock could rise by 17.97 percent from its current trading price. The potential increase for the stock is $317.25 per share, with a possible range of $170.00 to $380.00. If you are interested in AMGN stock, you should also look at its competitors.
17.97% Upside
Amgen Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Amgen's Price has fallen from $220.28 to $0.00 – a 100.00% decrease. In the next year, analysts expect Fair Value to reach $281.06 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$726.31 | Buy/Sell | $636.99 | 15.31% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr866.20 | Buy/Sell | kr696.07 | 10.83% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.51% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.41 | Buy/Sell | $178.42 | 13.57% |
Amgen Revenue Forecast for 2023 - 2025 - 2030
Amgen's Revenue has increased by 10.88% In the last three years, going from $25.42B to $28.19B. In the next year, analysts expect Revenue to reach $28.62B – an increase of 1.53%. By 2030, professionals believe that Amgen's Revenue will decrease by 0.48%, reaching $28.05B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£109.46 | Buy/Sell | £165.99 | 47.83% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$544.78 | Buy/Sell | $591.94 | 11.33% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.53 | Buy/Sell | CHF105.00 | 23.11% |
.jpg)
Amgen Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Amgen's Dividend per Share has grown, increasing from $6.40 to $8.52 – a growth of 33.13%. The next year looks promising for Amgen, with analysts predicting Dividend per Share of $9.30 – an increase of 9.15%. Over the next seven years, experts anticipate that Amgen's Dividend per Share will grow at a rate of 48.36%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF222.10 | Buy/Sell | CHF307.83 | 22.69% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.28 | Buy/Sell | $118.92 | 18.38% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$235.51 | Buy/Sell | $260.33 | 14.64% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.00 | Buy/Sell | $32.87 | 17.31% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
86.89€ | Buy/Sell | 102.80€ | 24.30% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.48 | Buy/Sell | $92.47 | 20.16% |
Amgen EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Amgen's EBITDA has gone down from $12.77B to $12.24B – a 4.17% drop. Next year, analysts are expecting EBITDA to reach $16.97B – an increase of 38.69%. Over the next seven years, the forecast is for EBITDA to grow by 6.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.93 | Buy/Sell | $58.15 | 12.41% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$896.82 | Buy/Sell | $961.26 | 17.08% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$66.76 | Buy/Sell | $87.82 | 22.83% |
Amgen EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Amgen's EBIT has fallen from $9.33B to $8.16B – a 12.48% decrease. For next year, analysts predict EBIT of $13.71B, which would mean an increase of 67.89%. Over the next seven years, experts predict that Amgen's EBIT will grow at a rate of 55.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.99 | Buy/Sell | £17.30 | 21.95% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
146.00€ | Buy/Sell | 190.06€ | 25.34% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$234.12 | Buy/Sell | $284.47 | 19.60% |
Amgen EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Amgen's EPS has fallen from $16.60 to $0.00 – a 100.00% decrease. In the next year, analysts expect EPS to reach $21.18 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.64k | Buy/Sell | ¥5.24k | 25.11% |
| MMM Stock Forecast | 3M | Hold |
10
|
$92.27 | Buy/Sell | $109.39 | 8.38% |
| BAS Stock Forecast | BASF | Outperform |
12
|
50.44€ | Buy/Sell | 49.50€ | 11.02% |
.jpg)